Epidermolysis Bullsosa (EB) is a painful genetic skin condition that causes the skin to tear or blister at the lightest touch. DEB (Dystrophic EB) is one of the most severe subsets of EB.
Our mission is to help patients with EB to live, and to live well.
By fulfilling our mission, we can transform the lives of people with DEB, as well as to develop and support technologies that can help cure thousands of other rare diseases that impact ~ 400m people worldwide.
Company Details
- Employees
- 3
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.abe-bio.com
- Keywords
- Ostrołęka.
Abe (Accelerating Breakthroughs In Eb) Questions
Abe (Accelerating Breakthroughs In Eb)'s website is http://www.abe-bio.com
Abe (Accelerating Breakthroughs In Eb)'s LinkedIn profile is https://www.linkedin.com/company/abe-accelerating-breakthroughs-in-eb
Abe (Accelerating Breakthroughs In Eb) has
3 employees.
View email and phone details for 3
employees at Abe (Accelerating Breakthroughs In Eb).
Abe (Accelerating Breakthroughs In Eb)'s industry is
Biotechnology Research
Abe (Accelerating Breakthroughs In Eb)'s top competitors are
Huckletree,
Debra International,
Zencargo,
General Projects,
Nonsense Tx,
Eb Clinet,
Termeer Institute,
Alderway Partnership Capital,
4k Cowork,
Cure Eb.
Abe (Accelerating Breakthroughs In Eb)'s categories are Biotechnology Research
Abe (Accelerating Breakthroughs In Eb)'s founding year is 2023
